KURA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kura Oncology Inc (KURA) does not present a strong buy opportunity for a beginner, long-term investor with $50,000-$100,000 available for investment. While the stock has shown some positive momentum in the short term, the lack of significant news catalysts, insider selling, and a bearish probability for the next month make it less appealing for a long-term investment at this time.
The technical indicators show a bullish trend with MACD positively expanding, RSI at 72.452 (neutral zone), and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). However, the stock is nearing resistance levels at R2: 10.144, which may limit further upside in the short term.
Analysts have a positive outlook on the company's commercial asset, ziftomenib, with a $23-$25 price target, suggesting significant upside potential in the long term. SwingMax signal from 2026-06-15 has shown a 6.22% price increase since then.
Insiders are selling shares, with a 178.01% increase in selling activity over the last month. Hedge funds remain neutral, and there are no recent news catalysts. Stock trend analysis shows a 60% chance of a -4.9% decline in the next month.
No financial data available for analysis.
Analysts maintain a Buy/Outperform rating with price targets ranging from $23 to $25. However, execution risks and delays in first-line sales projections (moved to 2029 from 2027) are noted as concerns.
